News|Articles|April 1, 2026

7 Upcoming FDA Decisions in Q2 2026 to Watch

Discover the critical Q2 2026 FDA decisions for Dato-DXd in TNBC and Orca-T in blood cancers, set to transform survival outcomes and precision oncology care.

The second quarter of 2026 stands as a pivotal window for the oncology and hematology sectors, with several high-stakes FDA decisions poised to reshape the treatment landscape for complex malignancies. From novel antibody-drug conjugates to cutting-edge allogeneic T-cell immunotherapies, the upcoming regulatory rulings reflect a continued push toward precision medicine and improved survival outcomes for patients with limited options.